Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease
The invention provides an application of Burkange-29 in treatment of human coronavirus infected pulmonary mucosal epidemic diseases, and also provides a preparation method of the Burkange-29. The Burnage-29 realizes the effects of inhibiting virus growth and improving immunity by reducing the mouse...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BAO-LE CHAOLU BAI CHANGXI YE RIGUI SA QILA SUIHEI JIRIMU BATU ALATAN AORIGELE |
| description | The invention provides an application of Burkange-29 in treatment of human coronavirus infected pulmonary mucosal epidemic diseases, and also provides a preparation method of the Burkange-29. The Burnage-29 realizes the effects of inhibiting virus growth and improving immunity by reducing the mouse lung human coronavirus 229E load and improving the percentage of peripheral blood CD4 + and CD8 + T lymphocytes so as to realize the purpose of treating the pulmonary mucosal disease. And meanwhile, the optimal dosage is defined. The number of the key action targets of the Burnage-29 is 10, and the key action targets are HIF1A, SYK, PTGS2, MAPK1, IL2, RELA, TLR4, IL6, STAT3 and TNF respectively.
本发明提供了布如那格-29用于治疗人冠状病毒感染肺黏疫病的用途；该布如那格-29通过降低小鼠肺部人冠状病毒229E载量和提高外周血CD4+及CD8+T淋巴细胞百分比来实现抑制病毒生长和提高免疫作用来实现治疗肺黏疫病的用途；同时明确了最佳给药计量。该布如那格-29的作用关键靶点为10个，分别为：HIF1A，SYK，PTGS2，MAPK1，IL2，RELA，TLR4，IL6，STAT3，TNF。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN116211957A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN116211957A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN116211957A3</originalsourceid><addsrcrecordid>eNqNijsKwkAQQNNYiHqH8QApNqKSMgbFyso-DJOJDuzOLvsRvL0RPIDVg_fesqIuBCuEWbyCn-BUouKD66YFUciRMTvW_E3P4lCBfPSKL4klzcfElHmEUKybbXyDK-Q5yMhOCEZJjInX1WJCm3jz46raXs73_lpz8AOngMTKeehvxhwaY9r9sdv983wAjgM-oA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease</title><source>esp@cenet</source><creator>BAO-LE CHAOLU ; BAI CHANGXI ; YE RIGUI ; SA QILA ; SUIHEI ; JIRIMU BATU ; ALATAN AORIGELE</creator><creatorcontrib>BAO-LE CHAOLU ; BAI CHANGXI ; YE RIGUI ; SA QILA ; SUIHEI ; JIRIMU BATU ; ALATAN AORIGELE</creatorcontrib><description>The invention provides an application of Burkange-29 in treatment of human coronavirus infected pulmonary mucosal epidemic diseases, and also provides a preparation method of the Burkange-29. The Burnage-29 realizes the effects of inhibiting virus growth and improving immunity by reducing the mouse lung human coronavirus 229E load and improving the percentage of peripheral blood CD4 + and CD8 + T lymphocytes so as to realize the purpose of treating the pulmonary mucosal disease. And meanwhile, the optimal dosage is defined. The number of the key action targets of the Burnage-29 is 10, and the key action targets are HIF1A, SYK, PTGS2, MAPK1, IL2, RELA, TLR4, IL6, STAT3 and TNF respectively.
本发明提供了布如那格-29用于治疗人冠状病毒感染肺黏疫病的用途；该布如那格-29通过降低小鼠肺部人冠状病毒229E载量和提高外周血CD4+及CD8+T淋巴细胞百分比来实现抑制病毒生长和提高免疫作用来实现治疗肺黏疫病的用途；同时明确了最佳给药计量。该布如那格-29的作用关键靶点为10个，分别为：HIF1A，SYK，PTGS2，MAPK1，IL2，RELA，TLR4，IL6，STAT3，TNF。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230606&DB=EPODOC&CC=CN&NR=116211957A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230606&DB=EPODOC&CC=CN&NR=116211957A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BAO-LE CHAOLU</creatorcontrib><creatorcontrib>BAI CHANGXI</creatorcontrib><creatorcontrib>YE RIGUI</creatorcontrib><creatorcontrib>SA QILA</creatorcontrib><creatorcontrib>SUIHEI</creatorcontrib><creatorcontrib>JIRIMU BATU</creatorcontrib><creatorcontrib>ALATAN AORIGELE</creatorcontrib><title>Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease</title><description>The invention provides an application of Burkange-29 in treatment of human coronavirus infected pulmonary mucosal epidemic diseases, and also provides a preparation method of the Burkange-29. The Burnage-29 realizes the effects of inhibiting virus growth and improving immunity by reducing the mouse lung human coronavirus 229E load and improving the percentage of peripheral blood CD4 + and CD8 + T lymphocytes so as to realize the purpose of treating the pulmonary mucosal disease. And meanwhile, the optimal dosage is defined. The number of the key action targets of the Burnage-29 is 10, and the key action targets are HIF1A, SYK, PTGS2, MAPK1, IL2, RELA, TLR4, IL6, STAT3 and TNF respectively.
本发明提供了布如那格-29用于治疗人冠状病毒感染肺黏疫病的用途；该布如那格-29通过降低小鼠肺部人冠状病毒229E载量和提高外周血CD4+及CD8+T淋巴细胞百分比来实现抑制病毒生长和提高免疫作用来实现治疗肺黏疫病的用途；同时明确了最佳给药计量。该布如那格-29的作用关键靶点为10个，分别为：HIF1A，SYK，PTGS2，MAPK1，IL2，RELA，TLR4，IL6，STAT3，TNF。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNijsKwkAQQNNYiHqH8QApNqKSMgbFyso-DJOJDuzOLvsRvL0RPIDVg_fesqIuBCuEWbyCn-BUouKD66YFUciRMTvW_E3P4lCBfPSKL4klzcfElHmEUKybbXyDK-Q5yMhOCEZJjInX1WJCm3jz46raXs73_lpz8AOngMTKeehvxhwaY9r9sdv983wAjgM-oA</recordid><startdate>20230606</startdate><enddate>20230606</enddate><creator>BAO-LE CHAOLU</creator><creator>BAI CHANGXI</creator><creator>YE RIGUI</creator><creator>SA QILA</creator><creator>SUIHEI</creator><creator>JIRIMU BATU</creator><creator>ALATAN AORIGELE</creator><scope>EVB</scope></search><sort><creationdate>20230606</creationdate><title>Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease</title><author>BAO-LE CHAOLU ; BAI CHANGXI ; YE RIGUI ; SA QILA ; SUIHEI ; JIRIMU BATU ; ALATAN AORIGELE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN116211957A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BAO-LE CHAOLU</creatorcontrib><creatorcontrib>BAI CHANGXI</creatorcontrib><creatorcontrib>YE RIGUI</creatorcontrib><creatorcontrib>SA QILA</creatorcontrib><creatorcontrib>SUIHEI</creatorcontrib><creatorcontrib>JIRIMU BATU</creatorcontrib><creatorcontrib>ALATAN AORIGELE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BAO-LE CHAOLU</au><au>BAI CHANGXI</au><au>YE RIGUI</au><au>SA QILA</au><au>SUIHEI</au><au>JIRIMU BATU</au><au>ALATAN AORIGELE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease</title><date>2023-06-06</date><risdate>2023</risdate><abstract>The invention provides an application of Burkange-29 in treatment of human coronavirus infected pulmonary mucosal epidemic diseases, and also provides a preparation method of the Burkange-29. The Burnage-29 realizes the effects of inhibiting virus growth and improving immunity by reducing the mouse lung human coronavirus 229E load and improving the percentage of peripheral blood CD4 + and CD8 + T lymphocytes so as to realize the purpose of treating the pulmonary mucosal disease. And meanwhile, the optimal dosage is defined. The number of the key action targets of the Burnage-29 is 10, and the key action targets are HIF1A, SYK, PTGS2, MAPK1, IL2, RELA, TLR4, IL6, STAT3 and TNF respectively.
本发明提供了布如那格-29用于治疗人冠状病毒感染肺黏疫病的用途；该布如那格-29通过降低小鼠肺部人冠状病毒229E载量和提高外周血CD4+及CD8+T淋巴细胞百分比来实现抑制病毒生长和提高免疫作用来实现治疗肺黏疫病的用途；同时明确了最佳给药计量。该布如那格-29的作用关键靶点为10个，分别为：HIF1A，SYK，PTGS2，MAPK1，IL2，RELA，TLR4，IL6，STAT3，TNF。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN116211957A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Application of Burnage-29 in treatment of human coronavirus infected pulmonary mucoepidemic disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A28%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BAO-LE%20CHAOLU&rft.date=2023-06-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN116211957A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |